SPAF


Also found in: Acronyms.

SPAF

Vascular disease A clinical trial–Stroke Prevention in Atrial Fibrillation–comparing low-dose aspirin vs anticoagulation with warfarin in preventing stroke and systemic embolism–the 1º events in 150 Pts with A Fib. See Atrial fibrillation, Low-dose aspirin. Cf AFASAK, BAATAF.
Mentioned in ?
References in periodicals archive ?
SPAF 2006 continues to feed this appetite for European masters and offers widespread visibility for talented young Korean directors on the verge of breaking out.
Two similar studies published in 1998 were terminated early, in light of the SPAF III results.
The largest Air France pilots' union, SNPL, joined two smaller unions - Alter and Spaf - to launch the strike action on 2 February to demand higher pay, an issue that has allegedly caused tension since September.
PAF was defined by documentation of sinus rhythm during a specified time period prior to study enrollment, 12 months for SPAF I and II patients and 3 months for SPAF III patients.
However, on-treatment analysis of the SPAF II data demonstrates a reduction in risk for ischemic stroke of approximately 50% for patients taking warfarin compared with that for those taking aspirin.
Warfarin, aspirin ve plasebonun karsilastirildigi AFASAK, SPAF I, BAATAF, SPINAF, EAFT, SPAF II calismalarinda, warfarin ve aspirin tedavilerinin her birinin plaseboya gore strok riskini anlamli azalttigi, warfarinin ise aspirin ile karsilastirildiginda cok daha iyi sonuclar verdigini gostermistir (1).
The largest Air France pilots' union, SNPL, joined two smaller unions - Alter and Spaf - to demand higher pay, an issue that has allegedly caused tension since September.
Two unions, Alter and Spaf, representing a minority of Air France pilots, have called for the strike action.
The union's involved in the industrial action include Alter, SPAF and SNPNAC, which together represent about one fifth of the carrier's total 3,500 pilots, although Air France disputes that figure.
We also present a commercially focused analysis and KOL commentary on each product's potential in the VTE, SPAF & ACS indications together with consensus and individual scenario forecasts for each product to 2018.